Trial reportJournal of the American Heart Association2025
Association of Minimal Clinically Important Difference With Infarct Volume in Clinical Poststroke Outcomes.
Trial report in Journal of the American Heart Association, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Association of 24-Hour Computed Tomography Infarct Density on Functional Outcomes in Stroke: Secondary Analysis From the AcT Trial.Journal of the American Heart Association · 2026Trial
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundInfarct volume is an imaging biomarker of ischemic tissue injury strongly correlated with poststroke outcomes and reperfusion benefit. We aimed to evaluate the follow-up infarct volume (FIV) difference corresponding to a 1%, 5%, and 10% increase in probability of excellent functional outcomes after intravenous thrombolysis.
methodsData are from the AcT trial (Alteplase Compared to Tenecteplase in Patients With Acute Ischemic Stroke). Patients with 24-hour infarct volume segmentations were included. The primary outcome was excellent functional outcome (modified Rankin Scale score=0-1). Associations between outcomes and FIV were investigated with regression analyses adjusted for covariates. Sensitivity analyses examined patients with noncontrast computed tomography versus magnetic resonance imaging follow-up and those treated versus not treated with endovascular thrombectomy.
resultsThe study included 1478 patients (median age 74 years [interquartile range (IQR), 63-83], 48.2% female). Median FIV was 2.7 mL (IQR, 0-18.2), and 527 (35.7%) achieved excellent functional outcome. FIV was associated with excellent functional outcome: adjusted odds ratio, 0.97 (95% CI, 0.96-0.98) per 1-mL FIV increase. The median ΔFIV corresponding to a 1%, 5%, and 10% increase in adjusted probability of excellent functional outcomes were 1.5 mL (IQR, 1.4-1.9), 7.3 mL (IQR, 6.8-9.3), and 14.6 mL (IQR, 13.6-18.2), respectively. Results were consistent across follow-up imaging modality and endovascular thrombectomy subgroups.
conclusionsIn patients with acute ischemic stroke treated with intravenous thrombolysis, differences of ~1.5 mL, ~7 mL, and ~15 mL in FIV corresponded to a 1%, 5%, and 10% higher absolute probability of achieving excellent functional outcomes. These findings could inform the design of future clinical Phase 2 and proof-of-principle stroke trials that aim to use FIV as a key outcome measure.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.